$0.68
+0.02
(+3.66%)▲
Live
2.94%
Downside
Day's Volatility :5.04%
Upside
2.16%
16.41%
Downside
52 Weeks Volatility :93.93%
Upside
92.74%
Period | Vincerx Pharma Inc | Index (Russel 2000) |
---|---|---|
3 Months | -10.14% | 0.0% |
6 Months | -42.96% | 0.0% |
1 Year | -42.96% | 0.0% |
3 Years | -95.75% | -20.2% |
Market Capitalization | 19.4M |
Book Value | - $0.03 |
Earnings Per Share (EPS) | -1.78 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -74.06% |
Return On Equity TTM | -224.18% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -34.6M |
Diluted Eps TTM | -1.78 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.05 |
EPS Estimate Next Year | -0.76 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.22 |
What analysts predicted
Upside of 929.41%
Sell
Neutral
Buy
Vincerx Pharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Vincerx Pharma Inc | 11.19% | -42.96% | -42.96% | -95.75% | -96.65% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Vincerx Pharma Inc | NA | NA | NA | -1.05 | -2.24 | -0.74 | NA | -0.03 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Vincerx Pharma Inc | Buy | $19.4M | -96.65% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Vincerx Pharma Inc
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 104.6%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 282.3%
SAGE RHINO CAPITAL LLC
Octagon Capital Advisors LP
Point72 Asset Management, L.P.
Rock Springs Capital Management LP
Bank of America Corp
Vanguard Group Inc
vincerx is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
Organization | Vincerx Pharma Inc |
Employees | 42 |
CEO | Dr. Ahmed M. Hamdy M.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.68
+3.66%
Keyarch Acquisition Corp
$0.68
+3.66%
Connexa Sports Technologies Inc
$0.68
+3.66%
Us Value Etf
$0.68
+3.66%
First Wave Biopharma Inc
$0.68
+3.66%
Global X Msci Next Emerging
$0.68
+3.66%
Fat Projects Acquisition Corp
$0.68
+3.66%
Capital Link Global Fintech
$0.68
+3.66%
Applied Uv Inc
$0.68
+3.66%